Literature DB >> 32875590

On the relationship between association and surrogacy when both the surrogate and true endpoint are binary outcomes.

Paul Meyvisch1,2,3, Ariel Alonso2, Wim Van der Elst4, Geert Molenberghs2,3.   

Abstract

The relationship between association and surrogacy has been the focus of much debate in the surrogate marker literature. Recently, the individual causal association (ICA) has been introduced as a metric of surrogacy in the causal inference framework, when both the surrogate and the true endpoint are normally distributed and when both are binary. Earlier work on the normal case has demonstrated that, although the ICA and the adjusted association are related metrics, their relationship strongly depends on unidentifiable parameters and, consequently, the association between both endpoints conveys little information on the validity of the surrogate. In addition, in the normal setting, the magnitude of the ICA does not depend on the mean of the outcomes. The latter implies that identifiable parameters such as mean responses and treatment effects provide no information on the validity of the surrogate. In the present work it is shown that this is fundamentally different in the binary case. We demonstrate that the observed association between the outcomes as well as the success rates in both treatment groups are quite predictive for the ICA. It is shown that finding a good surrogate will be more likely when the association between the endpoints is large, there are sizeable treatment effects and the success rates for both endpoints are similar in both treatment groups. These results are demonstrated using extensive simulations and illustrated on a case study in multi-drug resistant tuberculosis.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  R package surrogate; causal inference; surrogate endpoint

Mesh:

Substances:

Year:  2020        PMID: 32875590     DOI: 10.1002/sim.8698

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Rethinking intercurrent events in defining estimands for tuberculosis trials.

Authors:  Tra My Pham; Conor D Tweed; James R Carpenter; Brennan C Kahan; Andrew J Nunn; Angela M Crook; Hanif Esmail; Ruth Goodall; Patrick Pj Phillips; Ian R White
Journal:  Clin Trials       Date:  2022-07-19       Impact factor: 2.599

Review 2.  A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.

Authors:  N K Hills; J Lyimo; P Nahid; R M Savic; C Lienhardt; P P J Phillips
Journal:  Trials       Date:  2021-08-03       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.